Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Alle Kategorien

Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines » Report
Glarner Kantonalbank lanciert Wärmehypothek zum Null-Tarif » Report
Roche Group: Genentech Press Release - December 12, 2021 » Report
Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study » Report
Remarquable résultat d'Helvetia (CH) Swiss Property Fund pour l'exercice 2021 » Report
Helvetia (CH) Swiss Property Fund posts strong result for the 2021 financial year » Report
Helvetia (CH) Swiss Property Fund mit starkem Ergebnis im Geschäftsjahr 2021 » Report
Forbo Holding: Rückkaufangebot zum Festpreis beendet » Report
Forbo Holding: Fixed-price buyback offer completed » Report
Roche: Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A » Report
Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine » Report
Credit Suisse Group announces appointments to the Executive Board in line with its new strategy; new Board of Directors leadership appointments to enhance governance of subsidiary Boards » Report
Bossard Gruppe: Veränderung in der Konzernleitung » Report
Bossard Group: Change in the Group Executive Committee » Report
SGS: Brazil Revises Compliance Date for Pacifier Conformity Identification Seals » Report
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies » Report
European Centre for Disease Prevention and Control: Epidemiological update: Omicron variant of concern (VOC) – data as of 11 December 2021 (12:00) » Report
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia » Report
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up » Report
Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab » Report